BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12788925)

  • 1. Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation.
    Georgel PT; Horowitz-Scherer RA; Adkins N; Woodcock CL; Wade PA; Hansen JC
    J Biol Chem; 2003 Aug; 278(34):32181-8. PubMed ID: 12788925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin.
    Nan X; Campoy FJ; Bird A
    Cell; 1997 Feb; 88(4):471-81. PubMed ID: 9038338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation.
    Fuks F; Hurd PJ; Wolf D; Nan X; Bird AP; Kouzarides T
    J Biol Chem; 2003 Feb; 278(6):4035-40. PubMed ID: 12427740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation.
    Nguyen CT; Gonzales FA; Jones PA
    Nucleic Acids Res; 2001 Nov; 29(22):4598-606. PubMed ID: 11713309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of the Rett syndrome protein, MeCP2, to methylated and unmethylated DNA and chromatin.
    Hansen JC; Ghosh RP; Woodcock CL
    IUBMB Life; 2010 Oct; 62(10):732-8. PubMed ID: 21031501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosomal regulation by MeCP2: structural and enzymatic considerations.
    Bowen NJ; Palmer MB; Wade PA
    Cell Mol Life Sci; 2004 Sep; 61(17):2163-7. PubMed ID: 15338046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.
    Jones PL; Veenstra GJ; Wade PA; Vermaak D; Kass SU; Landsberger N; Strouboulis J; Wolffe AP
    Nat Genet; 1998 Jun; 19(2):187-91. PubMed ID: 9620779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of metallothionein-i gene expression: differential regulation of methylated and unmethylated promoters by DNA methyltransferases and methyl CpG binding proteins.
    Majumder S; Kutay H; Datta J; Summers D; Jacob ST; Ghoshal K
    J Cell Biochem; 2006 Apr; 97(6):1300-16. PubMed ID: 16329111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The methyl-CpG binding transcriptional repressor MeCP2 stably associates with nucleosomal DNA.
    Chandler SP; Guschin D; Landsberger N; Wolffe AP
    Biochemistry; 1999 Jun; 38(22):7008-18. PubMed ID: 10353812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation.
    Lorincz MC; Schübeler D; Groudine M
    Mol Cell Biol; 2001 Dec; 21(23):7913-22. PubMed ID: 11689684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1.
    Kimura H; Shiota K
    J Biol Chem; 2003 Feb; 278(7):4806-12. PubMed ID: 12473678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rett syndrome: a surprising result of mutation in MECP2.
    Dragich J; Houwink-Manville I; Schanen C
    Hum Mol Genet; 2000 Oct; 9(16):2365-75. PubMed ID: 11005791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin.
    Nikitina T; Shi X; Ghosh RP; Horowitz-Scherer RA; Hansen JC; Woodcock CL
    Mol Cell Biol; 2007 Feb; 27(3):864-77. PubMed ID: 17101771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation-dependent silencing at the H19 imprinting control region by MeCP2.
    Drewell RA; Goddard CJ; Thomas JO; Surani MA
    Nucleic Acids Res; 2002 Mar; 30(5):1139-44. PubMed ID: 11861904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A WW domain binding region in methyl-CpG-binding protein MeCP2: impact on Rett syndrome.
    Buschdorf JP; Strätling WH
    J Mol Med (Berl); 2004 Feb; 82(2):135-43. PubMed ID: 14618241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells.
    Koizume S; Tachibana K; Sekiya T; Hirohashi S; Shiraishi M
    Nucleic Acids Res; 2002 Nov; 30(21):4770-80. PubMed ID: 12409468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2.
    Nan X; Meehan RR; Bird A
    Nucleic Acids Res; 1993 Oct; 21(21):4886-92. PubMed ID: 8177735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The solution structure of the domain from MeCP2 that binds to methylated DNA.
    Wakefield RI; Smith BO; Nan X; Free A; Soteriou A; Uhrin D; Bird AP; Barlow PN
    J Mol Biol; 1999 Sep; 291(5):1055-65. PubMed ID: 10518942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MeCP2 driven transcriptional repression in vitro: selectivity for methylated DNA, action at a distance and contacts with the basal transcription machinery.
    Kaludov NK; Wolffe AP
    Nucleic Acids Res; 2000 May; 28(9):1921-8. PubMed ID: 10756192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of transcription and chromatin by methyl-CpG binding protein MBD1.
    Nakao M; Matsui S; Yamamoto S; Okumura K; Shirakawa M; Fujita N
    Brain Dev; 2001 Dec; 23 Suppl 1():S174-6. PubMed ID: 11738867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.